Gilead Sciences, Inc. (NASDAQ:GILD) Position Boosted by Beacon Harbor Wealth Advisors Inc.

Beacon Harbor Wealth Advisors Inc. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 71,133 shares of the biopharmaceutical company’s stock after acquiring an additional 1,586 shares during the quarter. Gilead Sciences accounts for approximately 1.7% of Beacon Harbor Wealth Advisors Inc.’s holdings, making the stock its 23rd largest position. Beacon Harbor Wealth Advisors Inc.’s holdings in Gilead Sciences were worth $5,762,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Nilsine Partners LLC raised its position in shares of Gilead Sciences by 1.1% during the 3rd quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after purchasing an additional 127 shares during the period. Etesian Wealth Advisors Inc. increased its position in Gilead Sciences by 0.7% in the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after buying an additional 128 shares during the period. Financial Counselors Inc. lifted its stake in Gilead Sciences by 1.5% in the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after buying an additional 128 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 130 shares during the period. Finally, Institutional & Family Asset Management LLC grew its position in shares of Gilead Sciences by 10.3% during the third quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 140 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on GILD. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Cantor Fitzgerald cut their target price on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 7th. Morgan Stanley decreased their price target on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Finally, Mizuho cut their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $83.69.

Insider Buying and Selling at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

Gilead Sciences stock traded down $0.22 during trading hours on Thursday, hitting $65.29. The company had a trading volume of 2,740,160 shares, compared to its average volume of 7,421,412. Gilead Sciences, Inc. has a one year low of $64.63 and a one year high of $87.86. The firm has a market cap of $81.29 billion, a PE ratio of 180.94, a PEG ratio of 1.31 and a beta of 0.22. The firm has a 50-day moving average of $70.87 and a 200 day moving average of $76.01. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. Gilead Sciences’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.37 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.72%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.